breast

Key Epidemiology and Current Breast Cancer Screening Guidelines

  • Understanding Breast Health
      - Approx. 80% of breast complaints are benign.
      - Peak incidence for benign breast disorders: 20s–50s.
      - Peak incidence for breast cancer occurs in postmenopausal women with a median diagnosis age of around 62 years.

  • Breast Disorders Overview
      - Breast cancer is the most common non-skin cancer among women globally.
      - Approximately 1 in 8 women (~12%) will develop invasive breast cancer in their lifetime.

  • Population Recommendations per USPSTF Guidelines
      - Women aged 40–74 years:
        - Recommendation: Biennial (every 2 years) screening mammography.
        - Grade: B.
      - Women aged 75 years or older:
        - Insufficient evidence to assess the balance of benefits and harms.
        - Grade: I.
      - Women with dense breasts:
        - Insufficient evidence for supplemental screening (US or MRI) after a negative mammogram.
        - Grade: I.

  • Patient Self-Awareness
      - Although self-breast exams are not universally endorsed as a formal screening tool, around 90% of breast masses are first noticed by patients themselves.
      - Patient education on distinguishing normal vs. abnormal findings is crucial.
      - Effective self-exams should encompass both breasts, both axillae, and the entirety of the chest wall.
      - The best time to perform an exam is during the follicular phase of the menstrual cycle.
      - Recommended technique includes inspection followed by palpation in two positions:
        - Arms at sides.
        - Arms raised or hands on hips.
      - Supine position is preferred for palpation, particularly for large or pendulous breasts.

  • Importance of Screenings
      - In women over 40 years, mammography is frequently the first-line study for identifying breast mass.
      - Imaging of the contralateral breast should also occur when a clinically apparent mass is detected.
      - Lymph nodes should be imaged when feasible to seek out unrecognized abnormalities.

  • Potential Harms of Mammography
      - False-positive results leading to follow-up imaging and biopsies.
      - Psychological impacts including patient anxiety.
      - Risk of unnecessary treatment.
      - Radiation exposure risks.

High-Risk Females — Special Considerations

  • Risk-Reducing Strategies
      - It is recommended that high-risk females undergo early and regular screening mammograms.
      - Possible use of Tamoxifen for premenopausal women or Raloxifene/Anastrozole for postmenopausal women, noting increased endometrial hyperplasia risk with Tamoxifen and elevated thromboembolic events with both medications.
      - Prophylactic mastectomy may be considered for exceptionally high-risk patients (e.g., those with BRCA1/2 mutations).

  • Gail Risk Assessment Model
      - Most widely utilized tool for calculating 5-year and lifetime risk in women who have never had breast cancer, DCIS, or LCIS or strong family history.
      - If a strong family history of breast cancer is present, genetic testing for BRCA1/BRCA2 is recommended.
      - The assessment considers seven factors:
        - Age.
        - Race/ethnicity.
        - Age at menarche.
        - Age at first birth.
        - Number of first-degree relatives with breast cancer.
        - History of biopsy.
        - History of LCIS/DCIS.

  • Breast Anatomy Overview
      - Upper Outer Quadrant (UOQ) and Tail of Spence are most common locations for breast cancer.
      - Cooper's ligaments serve as suspensory ligaments providing support to the breast tissue.
      - Main lymphatic drainage system includes axillary lymph nodes; internal mammary nodes account for approximately 3% of lymph drainage.
      - In younger patients, tissue composition is denser with glandular tissue; in older patients, there is more fatty tissue predominance.

Clinical Breast Exam Findings

  • Normal Findings
      - Presence of bilateral symmetry (minor asymmetry is typically normal).
      - No skin dimpling, retraction, or erythema.
      - Absence of nipple inversion unless longstanding/chronic.
      - No spontaneous discharge from nipples.
      - Presence of mild nodularity may be considered normal, especially premenstrually.
      - No palpable lymphadenopathy.

  • Abnormal / Concerning Findings (Red Flags for Malignancy)
      - Size of mass greater than 2 cm.
      - Immobility (mass is fixed to skin or chest wall).
      - Poorly defined, irregular, or spiculated margins.
      - Firmness or hard consistency in the mass.
      - Skin dimpling or any changes in skin color.
      - Nipple retraction or scaling.
      - Any bloody discharge from the nipple.
      - Ipsilateral lymphadenopathy present.
      - Non-tender masses.
      - Peau d'orange: skin changes resembling orange peel indicative of lymphatic obstruction.

Nipple Discharge Color Guide

  • Concerning Nipple Discharge Types:
      - Bloody Discharge: Indicative of potential Intraductal Papilloma or Invasive Papillary Cancer.
      - Serous (clear) Discharge: Normal or associated with conditions like Duct Ectasia, OCP use, Fibrocystic changes, or early pregnancy.
      - Yellow Tinted Discharge: Associated with Fibrocystic changes, Duct Ectasia, or Galactocele.
      - Green Discharge: Suggests Ductal Ectasia or Fibrocystic changes.
      - Purulent Discharge: Indicates superficial or central breast abscess.
      - Brown Discharge: Associated with Fibrocystic changes and/or Duct Ectasia.

  • Indicators for Concern:
      - Spontaneous, bloody, unilateral, persistent discharge from a single duct, particularly if associated with a mass.

Performing & Documenting the Breast Exam

  • Clinical Breast Exam Steps
      - Step 1: Inspection
        - Patient should be seated with arms at her sides initially, then arms raised overhead and/or hands pressed on hips; this action contracts the pectoral muscles for better inspection.
        - If the patient has large/pendulous breasts, she should lean forward during inspection.
        - Look for: asymmetry, skin texture changes, nipple abnormalities, dimpling, skin retraction, or edema.
      - Step 2: Palpation
        - Have the patient first seated with arms at her sides and then supine with arms elevated overhead.
        - Use the pads of fingers with techniques such as radial, spiral, or strip for palpation.
        - Ensure the entire breast, including axillary tail, axillae, and the chest wall, are palpated.
        - Attempt to express any fluid from the nipple.

  • Sample SOAP Note Documentation
      - Subjective: 35-year-old female presents with a 2-week history of a painless mass in the right breast, discovered incidentally. No nipple discharge or skin changes, with no personal or family history of breast cancer. LMP 2 weeks prior.
      - Objective: Bilateral breast exam performed. Left breast: no masses, tenderness, skin changes, or discharge. Right breast: 1.5 cm firm, well-circumscribed, mobile, nontender mass palpated at the 2 o'clock position, 3 cm from the nipple. No nipple discharge, skin dimpling, or retraction. No axillary or supraclavicular lymphadenopathy bilaterally.

Breast Mass Descriptor Terminology

  • Approach to Breast Mass
      - Descriptors:
        - Location: indicated by clock position (e.g., 2 o'clock), distance from the nipple.
        - Size: measured in centimeters.
        - Shape: documented as round, oval, or irregular.
        - Consistency: identified as soft, firm, hard, or rubbery.
        - Borders: categorized as well-circumscribed or irregular/poorly defined.
        - Mobility: classified as mobile or fixed.
        - Tenderness: noted as tender or non-tender.
        - Skin/Nipple Changes: observed for dimpling, retraction, erythema, or scaling.

  • General Approach to Evaluation
      - History remains the most crucial component during the initial evaluation. Essential inquiries include: location, duration, discovery method of the mass, presence of nipple discharge, changes in size, relation to menstrual cycle, and risk factors for malignancy.
      - A dominant mass should always be presumed cancerous until proven otherwise via biopsy.
      - Recommended diagnostic imaging includes mammography and ultrasound.
      - For Women <40: Ultrasound is the most common initial modality applied; a mammogram follows if suspicious findings arise.
      - For Women >40: Mammogram is typically the first-choice study.
      - Clinical Pearl: Triple Test:
        - Comprises clinical breast examination, imaging (mammogram ± ultrasound), and core needle biopsy.
        - When all three agree (whether benign or malignant), the accuracy is greater than 99%. If any one test raises suspicion for cancer, a recommendation for excision is advised.

  • Nipple Discharge Evaluation
      - Must consider discharge color, whether it is bilateral or unilateral, number of ducts involved, whether it is spontaneous or requires manipulation.
      - Physical Exam: Observe for skin changes, palpate for masses/lymphadenopathy, and elicit secretions by pressing the base of the areola.
      - Labs: For bloody or serosanguinous discharge, employ guaiac card testing and cytology; check TSH, prolactin, and β-hCG levels.
      - Imaging recommended includes mammograms and ultrasounds for masses presenting with discharge.
      - Intervention for Bloody, Unilateral Discharge: Requires ductography and possible ductal excision.
      - Pathologic discharge diagnosis requires diagnostic mammogram as first-line test, possibly followed by ultrasound or MRI if initial tests yield negative results.

Approach to Breast Pain (Mastalgia)

  • Overview
      - Mastalgia is categorized into three types:
        - Cyclic Mastalgia (2/3 of cases):
          - Related to menstrual cycle, often occurring in the late luteal phase, generally bilateral, often radiating to the axilla.
        - Noncyclic Mastalgia (1/3 of cases):
          - Not associated with the menstrual cycle; typically unilateral; can be due to tumors, mastitis, cysts, trauma, medications, or idiopathic causes.
        - Extramammary Pain:
          - Can originate from rib fractures, shingles, fibromyalgia, angina, or chest wall trauma.

  • Mastalgia Treatment
      - First-line Management:
        - Involves reassurance, proper fitting of bras, weight reduction, and maintaining regular exercise.
        - Medication options: Acetaminophen (APAP) or NSAIDs, Vitamin E (400–800 IU/day), and Primrose oil (1000 mg TID).
      - Second-line Treatment Options:
        - Danazol (200 mg/day): FDA-approved, though side effects like hair loss, acne, weight gain, and voice deepening are notable.
        - Tamoxifen (SERM): Used off-label as a last resort, associated with endometrial hyperplasia, DVT, and hot flashes.

  • Breast Abscess
      - Common in lactating women; presents with a fluctuating mass, tenderness, induration, and erythematous skin.
      - Treatment typically includes incision and drainage (I&D), potential biopsy in non-lactating patients, and antibiotics to cover Staphylococcus aureus.

Fibroadenoma

  • Clinical Presentation
      - The most common benign breast tumor, constitutes approximately 50% of all breast biopsies.
      - Identified as a firm, rubbery, mobile, well-circumscribed mass, usually non-tender.
      - Typically occurs in late teens to early 20s, though can affect women up to age 55.
      - There exists an earlier age of onset in Black women.
      - Generally results in a slightly elevated risk of breast cancer when proliferative disease is identified.

Fibrocystic Changes of the Breast

  • Clinical Presentation
      - Characterized by solid, round, disc-like, rubbery, very mobile cysts.
      - Sizes vary from 1–5 cm in diameter; typically non-tender with no retraction signs.
      - Cysts generally do not change with the menstrual cycle but can grow and cause discomfort during pregnancy.
      - Best imaging modality in pre-menopausal patients is ultrasound, which is generally preferred over mammograms due to dense tissue interference.
      - If diagnosis is uncertain, biopsy methods include Fine Needle Aspiration (FNA), Core Needle Biopsy (preferred), and excisional biopsy.
      - Histological examination reveals mature smooth muscle cells.
      - Observation is often sufficient, as about 50% involute within 5 years.
      - Excision is advised if the cyst exceeds 3–4 cm, increases significantly in size, or becomes symptomatic.

Mastitis

  • Clinical Presentation
      - Mastitis commonly occurs in lactating women, particularly within the first three months post-delivery.
      - Characterized by sudden unilateral tenderness and localized swelling, frequently accompanied by symptoms of illness and fever.
      - Diagnosis is primarily clinical, often presenting with cracked or fissured nipples and surrounding skin involvement.

  • Common Etiological Agents
      - Common bacterial causes include Staphylococcus aureus, with increasing incidences of MRSA, and less frequently, Streptococcus pyogenes (Group A or B) and E. coli.

  • Treatment
      - Non-complicated mastitis can often be treated with antibiotics (e.g., Dicloxacillin or Cephalexin for general cases; consider TMP-SMX or Clindamycin for MRSA confirmed cases).
      - Always consider underlying inflammatory breast cancer in non-lactating patients presenting with mastitis symptoms.

Galactorrhea

  • Clinical Overview
      - Defined as physiologic nipple discharge that may be unrelated to pregnancy or breastfeeding, predominantly seen in women aged 20–35 who have been pregnant.

  • Etiologies
      - Most frequently linked with hyperprolactinemia, which can stem from ancillary conditions or medications such as anti-psychotics (e.g., Haldol), TCAs, SSRIs, and SNRIs, affecting neurotransmitters.
      - Common causes include:
        - Pituitary adenomas, chronic renal failure, hormone-secreting tumors, and hypothyroidism.

  • Management Strategies
      - Treatment primarily entails discontinuing any offending medications and addressing underlying health conditions.
      - Referrals to endocrinology may be warranted in persistent cases.

Intraductal Papilloma and Ductal Ectasia

  • Intraductal Papilloma
      - Presents as small, benign tumors growing from the lining of breast ducts, typically not palpable.
      - They are often responsible for clear or grossly bloody discharge, considered the second most frequent cause of nipple discharge in non-lactating breasts.
      - Risk factor awareness is important; definitive diagnosis and treatment involve duct excision.

  • Ductal Ectasia
      - Characterized by widened milk ducts, thickened walls, and fluid buildup leading to duct blockage.
      - Commonly results in non-spontaneous, multicolored, non-bloody bilateral nipple discharge, and may include nipple retraction.
      - Management: entails diagnosing underlying causes and removal/management of offending medications if required.

Breast Carcinoma

  • Epidemiology and Risk Factors
      - Breast carcinoma is the second most common malignancy among women following skin cancer.
      - Invasive Ductal Carcinoma (IDC) is the most prevalent type, composing 70–80% of cases, with a lifetime risk of 1 in 8 women.
      - The most significant risk factor remains age, with the risk increasing until early 60s and peaking in the 70s.
      - Approximately 75% of breast cancer patients have no identifiable risk factors.
      - The common location of tumor development is the Upper Outer Quadrant (Tail of Spence).
      - Initial signs often present as abnormalities in mammograms, with around 80% of cases initially perceived as palpable masses.

  • USPSTF Identified Risk Factors:
      - Age >65 years, race (Caucasian > African American), early menarche (<12 years), late menopause (>55 years), first live birth after age 35, lack of breastfeeding, personal or family histories of breast cancer, presence of BRCA1/BRCA2 mutations, high breast density, exposure to radiation of the chest, and lifestyle factors including obesity, smoking, and alcohol use.

Histologic Classification

  • Key Breast Cancer Types:
      - Invasive Ductal Carcinoma (IDC): Accounts for 70–80% of cases, typically presents as a firm irregular mass and is well visualized on mammograms.
      - Invasive Lobular Carcinoma (ILC): Comprising 5–15%; often multifocal and bilateral, typically harder to detect on physical exams and mammograms.
      - Ductal Carcinoma In Situ (DCIS): Non-invasive, shows malignant cells confined to mammary ducts; identified by clustered microcalcifications.
      - Lobular Carcinoma In Situ (LCIS): Usually bilateral and indicates a 25–30% risk of invasive cancer development within 15 years.
      - Inflammatory Breast Cancer: Rare (accounting for <3% of cases), highly aggressive, typically presents in an advanced stage (III/IV) at diagnosis, with a poor prognosis (5-year survival 30–70%).
        - Characterized by skin changes resembling orange peel (peau d'orange) due to lymphatic obstruction.
      - Paget's Disease of the Nipple: Rarely presents alone; usually associated with underlying carcinoma.
        - Symptoms may include eczematous changes on the nipple and thickening of the nipple skin.

  • Breast Cancer Receptor Status:
      - ER+/PR+: Indicate well-differentiated tumors with favorable prognosis; treatment options include anti-estrogen therapies like Tamoxifen, aromatase inhibitors.
      - HER2+: Generally fast-growing and aggressive types observed in about 20–30% of breast cancers; treated with targeted therapies such as Trastuzumab (Herceptin) and Pertuzumab (Perjeta).
      - Triple Negative: Lack of hormone receptors; associated with the poorest prognosis and treated with chemotherapy, radiation, and possibly immunotherapy.

Staging and Treatment Overview

  • Staging System:
      - The TNM staging system designates tumor size (T), lymph node involvement (N), and presence of distant metastases (M). This staging serves as the most reliable prognostic indicator.
      - Staging levels I–IV reflect increasing severity, most notably influenced by lymph node status and distant spread post-treatment.
      - Common metastasis sites are bones, lungs, brain, and liver.

  • Treatment Protocol:
      - Surgical resection is mandated for all patients diagnosed with invasive breast cancer, with procedures ranging from lumpectomy (breast conservation) plus radiation to total mastectomy.
      - The gold standard includes surgical resection accompanied by sentinel lymph node biopsy to ascertain lymph node involvement.
      - Treatment plans include adjuvant therapies like chemotherapeutic agents, SERMs, monoclonal antibodies targeting HER2, and aromatase inhibitors.
      - Localized non-metastatic disease has a clinical cure rate of 75–90%.
      - Following the treatment of early-stage breast cancer (Stage I, II, III), cure is typically achievable. The goal in metastatic conditions is palliative care, with routine follow-ups essential due to a high recurrence rate.

Diagnostic Tests for Breast Disorders

  • Breast Imaging Techniques:
      - Mammography:
        - Utilized for both screening in asymptomatic women and diagnostic evaluations of breast complaints.
        - Offers visibility of abnormalities approximately two years prior to mass palpation.
      - Ultrasound:
        - Particularly useful in younger patients and women with dense breast tissue; helps differentiate between cystic and solid masses.
      - BI-RADS system:
        - Developed by the National Cancer Institute and FDA to standardize mammography reporting, enhancing communication between healthcare providers.
      - Needle Aspiration and Biopsy:
        - Techniques including Fine Needle Aspiration (FNA) and core needle biopsy for diagnostic tissue acquisition, with specific indications and limitations for each type.

Summary of Common Breast Disorders

Benign Disorders

  • Fibrocystic Changes:
      - Presented as lumpy/bumpy textures in menstrually transitional women.
      - Typically requires reassurance and symptomatic treatment.

  • Fibroadenoma:
      - Often diagnosed in younger women and presents as a well-circumscribed, mobile mass.
      - Management may require observation or excision if growth is significant.

  • Mastitis:
      - Most prevalent among lactating women; treated with antibiotics and sometimes surgical I&D.

Malignant Disorders

  • Invasive Ductal Carcinoma (IDC):
      - Most commonly diagnosed breast cancer, presenting with variable symptoms.

  • Invasive Lobular Carcinoma (ILC):
      - Less frequently diagnosed, requiring special imaging techniques for detection.

  • Paget’s Disease:
      - Rare form of breast cancer affecting the nipple, necessitating thorough examination for underlying carcinoma.

  • Inflammatory Breast Cancer:
      - Rare, aggressive, needing prompt treatment decisions given its unique presentation.